Grand Medical Group

About us

Grand Medical Group AG is a group of pharmaceutical companies specialized in the development, production, registration and introduction into medical practice of modern innovative products based on organic, synthetic and herbal compounds.

read more

10 Kornmarkt Street, CH - 6004 Luzern, Switzerland

+41 415880810

Each 5 ml of syrup contains 30 mg ambroxol hydrochloride, oral solution 125 ml in bottle ? 1


ATC code: R05CB06, expectorants, excl. combinations with cough suppressants, mucolytics Preclinically, ambroxol has been shown to increase respiratory tract secretion. It enhances pulmonary surfactant production and stimulates ciliary activity. These actions result in improved mucus ?ow and transport (mucociliary clearance). Improvement of mucociliary clearance has been shown in clinical pharmacological studies. Enhancement of ?uid secretion and mucociliary clearance facilitates expectoration and eases cough.


Secretolytic therapy in acute and chronic bronchopulmonary diseases associated with abnormal mucus secretion and impaired mucus transport.

Ambroxol is indicated for the liquefaction of the mucus secretions of the respiratory tracts, in case of acute and chronic bronchoalveolar disorders (bronchitis, emphysema, tracheobronchitis, and chronic asthmatic bronchitis).

It is also indicated for the prevention of respiratory complications after retention of secretions following major surgical operations on the thorax - upper abdomen and after prolonged bed rest.

It must be administered concomitantly with the proper antibiotic during acute bronchitis exacerbations.